Home > Divisions > Rheumatology > Research

Rheumatology

AddThis

"share
Print

email this

Research
 

Overview

The Division of Pediatric Rheumatology is actively engaged in clinical research to improve the care of children with rheumatic disease. This includes research studies funded by the NIH and foundations, as well as industry.  We currently have active clinical trials in systemic juvenile arthritis, polyarticular juvenile idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, pediatric scleroderma, inflammatory eye disease, and drug safety.

Research Faculty

Name
Areas of Special Interest
Laura E. Schanberg, MD,
Co- Chief		Pain in children with arthritis, treatment of juvenile arthritis, atherosclerosis in pediatric systemic lupus erythematosus, clinical trials in rare childhood diseases
Egla C. Rabinovich, MD,
Co-Chief		Treatment of childhood rheumatic diseases, treatment of inflammatory eye disease, drug safety, childhood osteoporosis, treatment of juvenile dermatomyositis, classification and treatment of linear scleroderma
Pediatric rheumatology workforce, cost-effective treatments in rheumatic disease, systemic onset juvenile arthritis, localized scleroderma


Clinical Research

  • Clinical trial of atorvastatin in preventing atherosclerosis in pediatric lupus erythematosus
  • Testing efficacy measures for pediatric lupus studies
  • Clinical trial of early aggressive treatment in polyarticular juvenile idiopathic arthritis
  • Clinical trial of adalimumab treatment in young children (2 to <4) years old with active juvenile idiopathic arthritis
  • Clinical trial of tocilumab treatment in children with active systemic juvenile idiopathic arthritis
  • Clinical trial of rituximab treatment in juvenile dermatomyositis
  • Electronic daily diary assessment of pain in juvenile arthritis
  • Multicenter registry of infliximab use in childhood uveitis
  • Systemic lupus erythematosus tumor registry
  • Observational registry of adalimumab in children with juvenile idiopathic arthritis
  • Clinical trial of rilonacept treatment in systemic juvenile idiopathic arthritis
  • Developing disease activity measures in linear scleroderma
  • NIH Patient Reported Outcomes Measurement Information System (PROMIS) Pediatric item bank development to enhance health related quality of life reporting
  • Observational registry of childhood vasculitis
  • Enhanced drug safety and surveillance reporting project
  • Observational registry of celecoxib and NSAIDs in children with juvenile idiopathic arthritis

Translational Research

  • Nitric oxide metabolism in statin treated pediatric systemic lupus erythematosus
  • Microarray assessment in childhood lupus erythematosus
  • Endothelial progenitor cells in pediatric SLE and atherosclerosis

Clinical Trials
 

Safety in Juvenile Idiopathic Arthritis:  NSAIDS and Celebrex Evaluation Registry (SINCERE).  Multi-center, observational registry of patients with Juvenile Idiopathic Arthritis (JIA) treated in routine clinical practice with celecoxib or other NSAIDS and designed to collect longer-term safety and other data.  Sponsor: Pfizer.  PI: Egla Rabinovich, MD. 

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis (TREAT).  Multi-center, randomized, double-blind treatment study designed to compare early aggressive drug therapies in patients with poly-JIA and extended oligo-JIA.  Sponsor: NIAMS.  Collaborator: Amgen.  PI: Laura Schanberg, MD.

STRIVE:  A Long-term, Multi-center, Longitudinal Post-Marketing, Observational Registry of Humira in Children with Active Juvenile Idiopathic Arthritis Intending to Assess the Safety and Effectiveness of Humira in Pediatric Patients.  Sponsor: Abbott Laboratories.  PI: Egla Rabinovich, MD.  
 
Multi-center Registry of Infliximab Use for Childhood Uveitis.  Randomized, open label study examining efficacy.  Sponsor: Duke University.  PI: Egla Rabinovich, MD. 

ALR: Novel Lupus Biomarkers. Multi-center, prospective, observational study to assess systemic lupus erythematosus (SLE) disease activity, predict the development of lupus nephritis, and predict the response to therapy for SLE using blood RNA markers. Sponsor: Baylor Research Institute.  PI: Laura Schanberg, MD. 
 
ARCHIVE:  A Registry for Children with Vasculitis. Multi-center Canadian/US diagnostic registry for children with chronic vasculitis. Sponsor: The Hospital for Sick Children (HSC); British Columbia Children’s Hospital in Vancouver, Canada.  PI:  Egla Rabinovich, MD.  
 
CARRA-EDSS (Childhood Arthritis and Rheumatology Research Alliance – Enhanced Drug Safety Surveillance). Multi-center registry of JIA patients with either a Serious Adverse Event (SAE) or an Important Medical Event (IME) and is designed to facilitate the capture and reporting of these events via MedWatch forms. Sponsor: Pfizer. PI: Egla Rabinovich, MD.

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults (RAPPORT). Multi-center, NIH-funded, randomized, double-blinded study comparing two rilonacept treatment regimens in patients diagnosed with JIA.  PI:  Laura Schanberg, MD.    
 
Active Juvenile Idiopathic Arthritis Compassionate Use. Multi-center, interventional, open label study designed to determine the safety and effectiveness of adalimumab (Humira) treatment in children from 2 to 4 years old.  This compassionate use study is sponsored by Abbott. PI: Egla Rabinovich, MD. 
 
Pediatric Localized Scleroderma. CARRA-funded project aimed at developing disease activity measures in localized scleroderma patients.  PI: Egla Rabinovich, MD.   
 
Electronic Diary Assessment of Pain in Juvenile Arthritis. Uses hand held computers to get in-the-moment information about how child and parent experiences and mood affect children’s daily pain and functioning. Sponsor: National Institutes of Health. PI: Laura Schanberg, MD.